The IMvigor010 trial showed that Signatera-guided treatment with Tecentriq improved disease-free survival and overall ...

TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...

Johnson & Johnson ( JNJ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 10:30 AM EST ...

Men over 50 are being urged to take action as they face a higher risk of prostate cancer, a disease that affects up to one in ...

Bacteria can serve as couriers for these anti-cancer vaccines. Using genetic engineering, the genetic instructions (or DNA) ...

In patients with locally advanced muscle-invasive bladder cancer who have undergone radical cystectomy and chemotherapy, adjuvant radiotherapy improves survival outcomes compared to observation only.

Young cancer, rising health costs, and financial strain are reshaping America's healthcare system as more people under 50 ...

A groundbreaking new study has found that a combination of two drugs can boost survival rates in prostate cancer patients by ...

Exercise defeats cancer!” Over 700 people gathered at the main stadium of Yonsei University’s Sinchon Campus in Seoul’s Seodaemun District on the morning of the 8th, chanting these words before ...

Becoming a blockbuster in its third full year on the market put Gilead’s cancer treatment Trodelvy on a course to potentially justify the company’s $21 billion ...

Investigators have developed a prognostic model that may identify which patients with MIBC are suitable for bladder-preserving chemoradiation.